PharmaShots | Incisive News in 3 Shots

Subscribe Now

DARZALEX

PharmaShots Interview: Janssen’s Mark Wildgust Shares Insights on Imbruvica for Chronic Lymphocytic Leukemia and Darzalex for Multiple Myeloma

PharmaShots Interview: Janssen’s Mark Wildgust Shares Insights on Imbruvica for Chronic Lymphocytic Leukemia and Darzalex for Mult...

May 2, 2022

Xbrane Biopharma Seeks to Initiate the Development of Keytruda and Darzalex Biosimilar

Xbrane Biopharma Seeks to Initiate the Development of Keytruda and Darzalex Biosimilar

December 13, 2021

Janssen Presents Results of Darzalex (daratumumab) in P-III MAIA Study for Transplant Ineligible Patients with Multiple Myeloma at EHA 2021

Janssen Presents Results of Darzalex (daratumumab) in P-III MAIA Study for Transplant Ineligible Patients with Multiple Myeloma at...

June 14, 2021

The US FDA Approves Kyprolis (carfilzomib) + Darzalex (daratumumab) + Dexamethasone in Two Dosing Regimens for R/R Multiple Myeloma

The US FDA Approves Kyprolis (carfilzomib) + Darzalex (daratumumab) + Dexamethasone in Two Dosing Regimens for R/R Multiple Myelom...

August 21, 2020

Janssen's Darzalex (daratumumab- SC) Receives Health Canada Approval for the Treatment of Patients with Multiple Myeloma

Janssen's Darzalex (daratumumab- SC) Receives Health Canada Approval for the Treatment of Patients with Multiple Myeloma

August 4, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us